Page 575«..1020..574575576577..580590..»

Researchers uncover new details behind inflammation that promotes heart disease – EurekAlert

Posted: December 24, 2021 at 2:17 am

BOSTON High cholesterol and inflammation are key drivers of heart disease, and an inflamed buildup of lipids can cut off the blood supply through a coronary artery to cause a heart attack. Because white blood cells, which usually defend against infection, trigger inflammation in these situations, a team led by scientists at Massachusetts General Hospital (MGH) recently studied aspects related to the cells production. The groups insights, which are published in Nature Cardiovascular Research, could lead to new strategies to protect cardiovascular health.

In patients with heart disease, white blood cells are more numerous, says senior author Matthias Nahrendorf, MD, PhD, an investigator in MGHs Center for Systems Biology and a professor of radiology at Harvard Medical School. Many of these cells can be found in a plaquethe buildup of fats, cholesterol, and other substances in a blood vesselwhere they arrive after being born in the bone marrow and migrating through the blood stream. But what leads to their increased bone marrow output is not clear.

Through experiments conducted in human bone marrow and mice, Nahrendorf and his colleagues found that high blood pressure, atherosclerosis, and the occurrence of a heart attack each can cause changes in the number of blood vessels in the bone marrow. These hallmarks of cardiovascular disease also changed the bone marrow vessels structure and function and affected their release of factors that regulate white blood cell production and migration.

As a consequence, more white blood cells were available in the body, and this increase, called leukocytosis, propels inflammation everywhere, including in the arteries and the heart, explains Nahrendorf. This study will allow us to now examine how to reduce white blood cell production to normal values, thereby cooling off inflamed plaques anywhere in the body.

Co-authors include MGHs David Rohde, MD, Katrien Vandoorne, PhD and others.

Funding for the study was provided by the National Heart, Lung, and Blood Institute grant P01HL142494.

This study provides strong evidence that cardiovascular disease affects the bone marrow vasculature and consequently blood stem cell activity, said Michelle Olive, Ph.D., program officer in the Division of Cardiovascular Sciences at the National Heart, Lung, and Blood Institute, part of the National Institutes of Health. This work sheds new light on the important role played by the vascular bone marrow niche and how inflammation occurs. It could lead to new targets and treatments for heart disease, the leading cause of death.

About the Massachusetts General Hospital

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. TheMass General Research Instituteconducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in theU.S. News & World Reportlist of "Americas Best Hospitals."

Bone marrow endothelial dysfunction promotes myeloid cell expansion in cardiovascular disease

23-Dec-2021

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Go here to see the original:
Researchers uncover new details behind inflammation that promotes heart disease - EurekAlert

Posted in Stem Cells | Comments Off on Researchers uncover new details behind inflammation that promotes heart disease – EurekAlert

Future Meat Lands 308M in Biggest-Ever Cultured Meat Investment – Labiotech.eu

Posted: December 24, 2021 at 2:17 am

The Israeli firm Future Meat Technologies has raised a neat 308M ($347M) in the biggest financing round in the field of cultured meat to date. The company claims rapid progress in addressing scaling bottlenecks that slow the sectors growth.

A range of contributors pitched into the mammoth funding round including an undisclosed tech investor, ADM Ventures the venture capital arm of the US food processing giant Archer-Daniels-Midland and the UK-based Manta Ray Ventures.

Future Meat is one of many firms in the emerging cultured meat sector, where meat is grown directly from cultured animal cells. The goal is to reduce the amount of land, resources, and animal slaughter required to meet humanitys protein demand. Future Meat is developing a range of products including cell-based hamburgers, chicken breast, and kebab meat.

This financing consolidates Future Meats position as the leading player in the cultivated meat industry, just three years after our launch, said Yaakov Nahmias, founder and president of Future Meat, in a public statement.

In 2020, cultured meat firms globally raised 319m ($360M) six times more than in 2019. Future Meats 308M Series B round alone nearly matches this sum. With the cash in hand, Future Meat plans to build a large-scale production facility in the US in 2022. The firm is focusing on obtaining US approval of its cell-based chicken before it expands to other regions.

This year promises even more funding going to cultured meat companies. One example is Good Meat, the cultured meat arm of the US firm Eat Just, which has raised 236M ($267M) so far this year. Eat Justs cell-based chicken became the first cultured meat product to receive marketing approval last year when Singapore gave it the green light. Another Israeli cultured meat developer, Aleph Farms, raised 89M ($105M) in its own Series B round in July.

In Europe, meanwhile, multiple big rounds have been raised this year by the likes of Meatable, Gourmey, and Mosa Meat. And the Brazilian meat giant JBS acquired the Spanish cultured meat startup BioTech Foods in November.

Funding for cultivated meat companies through the end of [the third quarter of] 2021 was already up 184% compared to all of 2020, and this doesnt even take into account the $347M raised by Future Meat Technologies, said Carlotte Lucas, Corporate Engagement Manager at the Good Food Institute, a non-profit organization dedicated to accelerating research into meat alternatives.

A September article from The Counter voiced concerns over the economic performance of cultured meat technology; production plants will find it very difficult to compete at a large scale with traditional slaughterhouses. Reasons include the need for expensive serum to nourish the cells, and the requirement for costly cell growth facilities.

You can make a big plant, or you can make a clean plant, David Humbird, chemical engineer and author of a report on the cultured meat sector for the investment entity Open Philanthropy, told The Counter. So if you want to feed millions and millions of people, its got to be big. But if you want to do it with animal cells, its got to be clean. We need both, and you cant do that.

In November, Mosa Meat welcomed the analysis from The Counter in a detailed blog post, with the argument that scaling up the technology could be feasible with continued investments and innovation.

Its far too early to be certain if and when cultivated meat will be produced at industrial scales and affordable prices, noted Lucas. As weve seen with smartphones, solar panels and genome sequencing, many impactful technologies that now shape our lives were unimaginable before key scientific breakthroughs made them possible.

Cultivated meat companies and scientists have already successfully challenged many historical assumptions about animal cell culture, and we have far from exhausted the creativity of researchers in this field.

Nahmias disagreed with the criticism, saying that the calculations are based on stem cell approaches, which is different to Future Meats method. Instead of using stem cells or muscle cells as the basis for the meat, the company uses fibroblasts, which are the cells that make connective tissue such as scar tissue. These cells are more resilient than stem cells and can be grown in vats more easily.

Our proprietary media rejuvenation technology enables cell densities greater than 100 billion cells per liter, translating to production densities 10 times higher than the industrial standard, stated Nahmias.

According to Future Meats latest announcement, the company has already exceeded expectations in bringing down the cost of manufacturing its chicken meat. Each 110-gram chicken breast costs 1.50 ($1.70) to produce less than half of what it cost six months ago.

While 2020 saw soaring demand for meat alternatives, the last six months have seen stagnating consumer interest in plant-based meat products. In November, for example, Beyond Meats stock fell by 19% as its sales fell short of expectations. As cultured meat technology matures and enters the market, some analysts see cell-based meats outshining plant-based products in the coming years.

With everyone eating at home, Covid-19 created a unique atmosphere for incredible retail sales growth for plant-based foods, so its no surprise that the industry couldnt maintain that growth rate as the world started to open up, said Lucas. But if you take a step back and look at the overall trajectory of the industry, demand from consumers is continuing to grow.

I feel like the meat-alternative field is inherently limited, as most people still seek the real thing, said Nahmias. This is where cultured meat is fundamentally different from existing alternatives; we arent an alternative, we are the real thing.

23 December 2021: Article updated with comments from Future Meat Technologies

Cover image via Elena Resko

More:
Future Meat Lands 308M in Biggest-Ever Cultured Meat Investment - Labiotech.eu

Posted in Stem Cells | Comments Off on Future Meat Lands 308M in Biggest-Ever Cultured Meat Investment – Labiotech.eu

UTSW working to reprogram cells to strengthen immunity in geriatric patients – UT Southwestern

Posted: December 24, 2021 at 2:17 am

CD8 T cells are a type of white blood cells that are essential for the immune system to fight infections and cancer.

DALLAS Dec. 17, 2021 What if the key to aging well lies in reprogramming immune system cells to strengthen them against infections and cancer? Researchers at UT Southwestern are working to find out.

Tuoqi Wu, Ph.D., Assistant Professor of Immunology

Tuoqi Wu, Ph.D., Assistant Professor in the Department of Immunology and in the Harold C. Simmons Comprehensive Cancer Center, studies aging in immune cells. His groundbreaking work at UT Southwestern was recently recognized with a grant from the Glenn Foundation for Medical Research and the American Federation for Aging Research, part of a $2.26 million mulifaceted grant program in support of biomedical research on aging.

Dr. Wu will investigate potential opportunities to improve immunity using strategies to reverse age-driven decline in CD8 T cell immunity. The results from this study could help develop novel interventions to improve immune surveillance against infections and cancer, diseases associated with increased frequency in the elderly, Dr. Wu said.

CD8 T cells are a type of white blood cells and are essential for the immune system to fight infections. As people age, these cells become less effective in controlling infections, and the risk of infection-related hospitalizations, deaths, and cancer increases. In addition, vaccines are less protective in the elderly because they work by activating the immune system.

The UT Southwestern scientists recently discovered a type of CD8 T cells, termed stem cell-like CD8 T cells, which have longer lifespans and are more effective in combating infections and cancer. In this study, they will evaluate strategies to reverse age-driven decline in CD8 T cell immunity by reprograming the aged CD8 T cells into stem cell-like CD8 T cells.

UT Southwestern is ranked as one of the nations top 25 hospitals for both cancer and geriatric care.

UT SouthwesternsHarold C. Simmons Comprehensive Cancer Center, the only National Cancer Institute-designated comprehensive cancer center in North Texas, includes five research and 12 clinical care programs with a focus on fostering groundbreaking translational research that can improve patient treatment, address cancer health disparities, and prevent cancer worldwide. In addition, the Centers education and training programs support and develop the next generation of cancer researchers and clinicians. The comprehensive designation and associated funding is designed to bolster the cancer centers research and to provide patients access to innovative clinical trials with promising new drugs. Simmons Cancer Center members currently have over $90 million in extramural cancer-focused research funding.

About UTSouthwestern Medical Center

UTSouthwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institutions faculty has received six Nobel Prizes, and includes 25 members of the National Academy of Sciences, 16 members of the National Academy of Medicine, and 14 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,800 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UTSouthwestern physicians provide care in about 80 specialties to more than 117,000 hospitalized patients, more than 360,000 emergency room cases, and oversee nearly 3 million outpatient visits a year.

View post:
UTSW working to reprogram cells to strengthen immunity in geriatric patients - UT Southwestern

Posted in Stem Cells | Comments Off on UTSW working to reprogram cells to strengthen immunity in geriatric patients – UT Southwestern

COVID-19 vaccine is a gift that is saving lives – CatholicPhilly.com

Posted: December 24, 2021 at 2:16 am

By Catholic News Service Posted December 23, 2021

The following editorial was published online Dec. 17 by Our Sunday Visitor, a national Catholic newsweekly based in Huntington, Indiana. It was written by the editorial board.

***

This time last year, when we flipped the calendar from 2020 to 2021, many glasses were raised to toast what we all hoped would be a better year ahead. 2020 was so difficult for so many. Too many of us saw sickness and death up close as we mourned the loss of 350,000 people in the United States who had died from COVID-19 mothers and fathers, sisters and brothers, grandparents, aunts, uncles, friends and so many more.

We sheltered in place and longed for the physical closeness that we had previously taken for granted. Our beloved Masses were canceled in order to protect ourselves and our neighbors, especially our elderly brothers and sisters and others who were significantly vulnerable to the virus.

We masked up, washed our hands and socially distanced, hoping that these small sacrifices might help to flatten the curve and ease the overwhelming burden that had been placed on our health care workers the doctors and nurses and others who Pope Francis called the unsung heroes of this pandemic.

Aside from masking and washing and distancing, there was little we could do other than pray that God would lead us out of the darkness. Even amid our suffering, we can be confident that he hears our cries, as Scripture assures us. When you call me, and come and pray to me, I will listen to you (Jer 29:12-13). In the Gospel of Matthew, Jesus himself says, Ask and it will be given to you; seek and you will find; knock and the door will be opened to you (7:7-8).

In the twilight days of 2020, that door was opened. After months of research and trials, scientists and medical researchers produced a number of vaccines that were approved for emergency use by the public, and on Dec. 11, 2020, the vaccine rollout began a stunning, unprecedented success by the scientific community.

Ten days after the first doses were given in the United States, on Dec. 21, 2020, the Vaticans Congregation for the Doctrine of the Faith attempted to put to rest growing concerns over the use of fetal stem cells in the development of the vaccines, ruling not only that the use of the approved vaccines was morally licit but that the morality of vaccination depends not only on the duty to protect ones own health, but also on the duty to pursue the common good. Pope Francis and the U.S. bishops called receiving the vaccine an act of love.

With vaccination medically and morally approved, it seemed likely that COVID-19 would largely be snuffed out in 2021. Optimism abounded, and by mid-April, a quarter of the U.S. population was fully vaccinated; we reached 50% by the end of July. Since then, progress has stalled as of mid-December, just 60% of Americans are fully vaccinated and the consequences have been dire.

After tragically losing 350,000 people to COVID in 2020, 450,000 more people were killed by the virus in 2021 an almost unfathomable amount considering that an effective vaccine is available. Sadly, the data makes it clear that the vast majority of COVID-19 deaths in 2021 were preventable. According to the Centers for Disease Control and Prevention, those who are fully vaccinated are more than 10 times less likely to be hospitalized or die from COVID-19.

Some would argue that the rise in breakthrough cases those who contract the virus despite being fully vaccinated is evidence that the vaccines are ineffective. No vaccine is 100% effective in preventing contraction of a virus or disease; its effectiveness lies in the ability to ward off serious symptoms that lead to hospitalizations and death, as the statistics above show.

As new variants such as omicron spread, and more time passes since the vaccine was received, breakthrough cases will continue to rise. This is why health care professionals are urging those who qualify to get a booster shot something that our culture doesnt see as controversial when it protects us against tetanus or shingles or hepatitis or myriad other maladies.

Perhaps well need a yearly COVID-19 booster just as we have annual flu shots. If it protects us from serious illness or worse it seems well worth it.

The same can be said for the vaccine itself. Its time for those who are unvaccinated to stop moving the bar. First, it was a moral objection, one that the CDF, the U.S. bishops and the pope himself have cleared up. Then came the claim that there was not enough data to prove that the vaccine is safe and effective; study after study has shown those concerns were unfounded. The next complaint was that the vaccines were only approved on an emergency basis; that, too, is no longer the case.

The science is sound, and the numbers tell the story. Of the 450,000 people who have died this year, how many could have been saved had they received the vaccine?

For centuries, critics of the Catholic faith have argued that the church is anti-science. They couldnt be further from the truth. Toward the end of the Second Vatican Council, Pope St. Paul VI spoke to men of thought and science, telling them, Never perhaps, thank God, has there been so clear a possibility as today of a deep understanding between real science and real faith, mutual servants of one another in the one truth.

Todays truth is simple: The COVID-19 vaccine is a gift. If we accept it, we honor the churchs teaching that calls us to protect all human life. If we continue to reject it, we must ask: What will the death toll be when we flip the calendar again?

***

The views or positions presented in this or any guest editorial are those of the individual publication and do not necessarily represent the views of CatholicPhilly.com, Catholic News Service or the U.S. Conference of Catholic Bishops.

More:
COVID-19 vaccine is a gift that is saving lives - CatholicPhilly.com

Posted in Indiana Stem Cells | Comments Off on COVID-19 vaccine is a gift that is saving lives – CatholicPhilly.com

Stem Cell Therapy: a Look at Current Research, Regulations …

Posted: December 24, 2021 at 2:11 am

P T. 2014 Dec; 39(12): 846-847, 854-857.

Ms. Reisman is a freelance medical writer living near Philadelphia, Pennsylvania. Ms. Adams is a Pennsylvania-based independent journalist.

Disclosure: The authors report that they have no commercial or financial relationships in regard to this article.

In September 2014, the Sanford Stem Cell Clinical Center at the University of California, San Diego (UCSD) Health System announced the launch of a groundbreaking clinical trial to assess the safety of neural stem cellbased therapy in patients with chronic spinal cord injury. Researchers hope that the transplanted stem cells will develop into new neurons that replace severed or lost nerve connections and restore at least some motor and sensory function.1

Two additional clinical trials at UCSD are testing stem cellderived therapy for type-1 diabetes and chronic lymphocytic leukemia, the most common form of blood cancer.1

These three studies are significant in that they are among the first efforts in stem cell research to make the leap from laboratory to human clinical trials. While the number of patients involved in each study is small, researchers are optimistic that as these trials progress and additional trials are launched, a greater number of patients will be enrolled. UCSD reports that trials for heart failure, amyotrophic lateral sclerosis, and blindness are in planning stages.1

The study of stem cells offers great promise for better understanding basic mechanisms of human development, as well as the hope of harnessing these cells to treat a wide range of diseases and conditions.2 However, stem cell research particularly human embryonic stem cell (hESC) research, which involves the destruction of days-old embryoshas also been a source of ongoing ethical, religious, and political controversy.2

In 1973, the Department of Health, Education, and Welfare (now the Department of Health and Human Services) placed a moratorium on federally funded research using live human embryos.3,4 In 1974, Congress adopted a similar moratorium, explicitly including in the ban embryos created through in vitro fertilization (IVF). In 1992, President George H.W. Bush vetoed legislation to lift the ban, and in 2001, President George W. Bush issued an executive order banning federal funding on stem cells created after that time.3,4 Some states, however, have permitted their limited use. New Jersey, for example, allows the harvesting of stem cells from cloned human embryos, whereas several other states prohibit the creation or destruction of any human embryos for medical research.3,4

In 2009, shortly after taking office, President Barack Obama lifted the eight-year-old ban on federally funded stem cell research, allowing scientists to begin using existing stem cell lines produced from embryos left over after IVF procedures.5 (A stem cell line is a group of identical stem cells that can be grown and multiplied indefinitely.)

The National Institutes of Health (NIH) Human Embryonic Stem Cell Registry6 lists the hESCs eligible for use in NIH-funded research. At this writing, 283 eligible lines met the NIHs strict ethical guidelines for human stem cell research pertaining to the embryo donation process.7 For instance, to get a human embryonic stem cell line approved, grant applicants must show that the embryos were donated by individuals who sought reproductive treatment and who gave voluntary written consent for the human embryos to be used for research purposes. 8 The ESCs used in research are not derived from eggs fertilized in a womans body.9

Because of the separate legislative ban, it is still not possible for researchers to create new hESC lines from viable embryos using federal funds. Federal money may, however, be used to research lines that were derived using private or state sources of funding.5

While funding restrictions and political debates may have slowed the course of stem cell research in the United States,10 the field continues to evolve. This is evidenced by the large number of studies published each year in scientific journals on a wide range of potential uses across a variety of therapeutic areas.1113

The Food and Drug Administration (FDA) has approved numerous stem cellbased treatments for clinical trials. A 2013 report from the Pharmaceutical Research and Manufacturers of America lists 69 cell therapies as having clinical trials under review with the FDA, including 15 in phase 3 trials. The therapeutic categories represented in these trials include cardiovascular disease, skin diseases, cancer and related conditions, digestive disorders, transplantation, genetic disorders, musculoskeletal disorders, and eye conditions, among others.14

Still, the earliest stem cell therapies are likely years away. To date, the only stem cellbased treatment approved by the FDA for use in this country is for bone marrow transplantation.15 As of 2010 (the latest year for which data are available), more than 17,000 blood cancer patients had had successful stem cell transplants.16

Research on stem cells began in the late 19th century in Europe. German biologist Ernst Haeckel coined the term stem cell to describe the fertilized egg that becomes an organism.17

In the U.S., the study of adult stem cells took off in the 1950s when Leroy C. Stevens, a cancer researcher based in Bar Harbor, Maine, found large tumors in the scrotums of mice that contained mixtures of differentiated and undifferentiated cells, including hair, bone, intestinal, and blood tissue. Stevens and his team concluded that the cells were pluripotent, meaning they could differentiate into any cell found in a fully grown animal. Stem cell scientists are using that carefully documented research today.17

In 1968, Robert A. Good, MD, PhD, at the University of Minnesota, performed the first successful bone marrow transplant on a child suffering from an immune deficiency. Scientists subsequently discovered how to derive ESCs from mouse embryos and in 1998 developed a method to take stem cells from a human embryo and grow them in a laboratory.17

Many degenerative and currently untreatable diseases in humans arise from the loss or malfunction of specific cell types in the body.9 While donated organs and tissues are often used to replace damaged or dysfunctional ones, the supply of donors does not meet the clinical demand.18 Stem cells seemingly provide a renewable source of replacement cells and tissues for transplantation and the potential to treat a myriad of conditions.

Stem cells have two important and unique characteristics: First, they are unspecialized and capable of renewing themselves through cell division. When a stem cell divides, each new cell has the potential either to remain a stem cell or to differentiate into other kinds of cells that form the bodys tissues and organs. Stem cells can theoretically divide without limit to replenish other cells that have been damaged.9

Second, under certain controlled conditions, stem cells can be induced to become tissue- or organ-specific cells with special functions. They can then be used to treat diseases affecting those specific organs and tissues. While bone marrow and gut stem cells divide continuously throughout life, stem cells in the pancreas and heart divide only under appropriate conditions.9

There are two main types of stem cells: 1) embryonic stem cells (ESCs), found in the embryo at very early stages of development; and 2) somatic or adult stem cells (ASCs), found in specific tissues throughout the body after development.9

The advantage of embryonic stem cells is that they are pluripotentthey can develop into any of the more than 200 cell types found in the body, providing the potential for a broad range of therapeutic applications. Adult stem cells, on the other hand, are thought to be limited to differentiating into different cell types of their tissue of origin.9 Blood cells, for instance, which come from adult stem cells in the bone marrow, can specialize into red blood cells, but they will not become other cells, such as neurons or liver cells.

A significant advantage of adult stem cells is that they offer the potential for autologous stem cell donation. In autologous transplants, recipients receive their own stem cells, reducing the risk of immune rejection and complications. Additionally, ASCs are relatively free of the ethical issues associated with embryonic stem cells and have become widely used in research.

Representing a relatively new area of research, induced pluripotent stem cells (iPSCs) are adult stem cells that have been genetically reprogrammed back to an embryonic stem celllike state. The reprogrammed cells function similarly to ESCs, with the ability to differentiate into any cell of the body and to create an unlimited source of cells. So iPSCs have significant implications for disease research and drug development.

Pioneered by Japanese researchers in 2006, iPSC technology involves forcing an adult cell, such as a skin, liver, or stomach cell, to express proteins that are essential to the embryonic stem cell identity. The iPSC technology not only bypasses the need for human embryos, avoiding ethical objections, but also allows for the generation of pluripotent cells that are genetically identical to the patients. Like adult cells, these unlimited supplies of autologous cells could be used to generate transplants without the risk of immune rejection.9

In 2013, researchers at the Spanish National Cancer Research Centre in Madrid successfully reprogrammed adult cells in mice, creating stem cells that can grow into any tissue in the body. Prior to this study, iPSCs had never been grown outside Petri dishes in laboratories.19 And, in July 2013, Japans health minister approved the first use of iPSCs in human trials. The Riken Center for Developmental Biology will use the cells to attempt to treat age-related macular degeneration, a common cause of blindness in older people. The small-scale pilot study would test the safety of iPSCs transplanted into patients eyes.20

According to David Owens, PhD, Program Director of the Neuroscience Center at NIHs National Institute of Neurological Disorders and Stroke (NINDS), one of the fundamental hurdles to using stem cells to treat disease is that scientists do not yet fully understand the diseases themselves, that is, the genetic and molecular signals that direct the abnormal cell division and differentiation that cause a particular condition. You want that before you propose a therapeutic, he says, because you want a firm, rational basis for what youre trying to do, what youre trying to change.

Although most of the media attention around stem cells has focused on regenerative medicine and cell therapy, researchers are finding that iPSCs, in particular, hold significant promise as tools for disease modeling.21,22 A major barrier to research is often inaccessibility of diseased tissue for study.23 Because iPSCs can be derived directly from patients with a given disease, they display all of the molecular characteristics associated with the disease, thereby serving as useful models for the study of pathological mechanisms.

The biggest payoff early on will be using these cells as a tool to understand the disease better, says Dr. Owens. For instance, he explains that creating dopamine neurons from iPSC lines could help scientists more closely study the mechanisms behind Parkinsons disease. If we get a better handle on the disorders themselves, then that will also help us generate new therapeutic targets. Recent studies show the use of these patient-specific cells to model other neurodegenerative disorders, including Alzheimers and Huntingtons diseases.2426

In addition to using iPSC technology, it is also possible to derive patient-specific stem cell lines using an approach called somatic cell nuclear transfer (SCNT). This process involves adding the nuclei of adult skin cells to unfertilized donor oocytes. As reported in spring 2014, a team of scientists from the New York Stem Cell Foundation Research Institute and Columbia University Medical Center used SCNT to create the first disease-specific embryonic stem cell line from a patient with type-1 diabetes. The insulin-producing cells have two sets of chromosomes (the normal number in humans) and could potentially be used to develop personalized cell therapies.27

The development of iPSCs and related technologies may help address the ethical concerns and open up new possibilities for studying and treating disease, but there are still barriers to overcome. One major obstacle is the tendency of iPSCs to form tumors in vivo. Using viruses to genomically alter the cells can trigger the expression of cancer-causing genes, or oncogenes.28

Much more research is needed to understand the full nature and potential of stem cells as future medical therapies. It is not known, for example, how many kinds of adult stem cells exist or how they evolve and are maintained.9

Some of the challenges are technical, Dr. Owens explains. For instance, generating large enough numbers of a cell type to provide the amounts needed for treatment is difficult. Some adult stem cells have a very limited ability to divide, making it difficult to multiply them in large numbers. Embryonic stem cells grow more quickly and easily in the laboratory. This is an important distinction because stem cell replacement therapies require large numbers of cells.29

Also, says Dr. Owens, stem cell transplants present immunological hurdles: If you do introduce cells into a tissue, will they be rejected if theyre not autologous cells? Or, you might have immunosuppression with the individual who received the cells, and then there are additional complications involved with that. Thats still not entirely clear.

Such safety issues need to be addressed before any new stem cellbased therapy can advance to clinical trials with real patients. According to Dr. Owens, the preclinical testing stage typically takes about five years. This would include assessment of toxicity, tumorigenicity, and immunogenicity of the cells in treating animal models for disease.30

Those are things we have to continually learn about and try to address. It will take time to understand them better, Dr. Owens says. Asked about the importance of collaboration in overcoming the scientific, regulatory, and financial challenges that lie ahead, he says, Its unlikely that one entity could do it all alone. Collaboration is essential.

Ultimately, stem cells have huge therapeutic potential, and numerous studies are in progress at academic institutions and biotechnology companies around the country. Studies at the NIH span multiple disciplines, notes Dr. Owens, who oversees funding for stem cell research at NINDS. ( shows the recent history of NIH funding for stem cell research.) He describes one area of considerable interest as the promotion of regeneration in the brain based on endogenous stem cells. Until recently, it was believed that adult brain cells could not be replaced. However, the discovery of neurogenesis in bird brains in the 1980s led to startling evidence of neural stem cells in the human brain, raising new possibilities for treating neurodegenerative disorders and spinal cord injuries.31

Its a fascinating idea, says Dr. Owens. Its unclear still what the functions of those cells are. They could probably play different roles in different species, but just the fundamental properties themselves are very interesting. He cites a number of NINDS-funded studies looking at those basic properties.

In another NIH-funded study, Advanced Cell Technology (ACT), a Massachusetts-based biotechnology company, is testing the safety of hESC-derived retinal cells to treat patients with an eye disease called Stargardts macular dystrophy. A second ACT trial is testing the safety of hESC-derived retinal cells to treat age-related macular degeneration patients.32,33

In April 2014, scientists at the University of Washington reported that they had successfully regenerated damaged heart muscles in monkeys using heart cells created from hESCs. The research, published in the journal Nature, was the first to show that hESCs can fully integrate into normal heart tissue.34

The study did not answer every question and had its complicationsit failed to show whether the transplanted cells improved the function of the monkeys hearts, and some of the monkeys developed arrhythmias.34,35 Still, the researchers are optimistic that it will pave the way for a human trial before the end of the decade and lead to significant advances in treating heart disease.29

In May 2014, Asterias Biotherapeutics, a California-based biotechnology company focused on regenerative medicine, announced the results of a phase 1 clinical trial assessing the safety of its product AST-OPC1 in patients with spinal cord injuries.36 The study represents the first-in-human trial of a cell therapy derived from hESCs. Results show that all five subjects have had no serious adverse events associated with the administration of the cells, with the AST-OPC1 itself, or with the immunosuppressive regimen. A phase 1/2a dose-escalation study of AST-OPC1 in patients with spinal cord injuries is awaiting approval from the FDA.37

The FDA itself has a team of scientists studying the potential of mesenchymal stem cells (MSCs), adult stem cells traditionally found in the bone marrow. Multipotent stem cells, MSCs differentiate to form cartilage, bone, and fat and could be used to repair, replace, restore, or regenerate cells, including those needed for heart and bone repair.38

Publicly available information about federally and privately funded clinical research studies involving stem cells can be found at http://clinicaltrials.gov. However, the FDA cautions that the information provided on that site is supplied by the product sponsors and is not reviewed or confirmed by the agency.

The biggest payoff early on will be using these cells as a tool to understand the disease better. If we get a better handle on the disorders themselves, then that will also help us generate new therapeutic targets.

David Owens, PhD, Program Director, Neuroscience Center, National Institute of Neurological Disorders and Stroke

Stem cell research policy varies significantly throughout the world as countries grapple with the scientific and social implications. In the European Union, for instance, stem cell research using the human embryo is permitted in Belgium, Britain, Denmark, Finland, Greece, the Netherlands, and Sweden; however, it is illegal in Austria, Germany, Ireland, Italy, and Portugal.39

In those countries where cell lines are accessible, research continues to create an array of scientific advances and widen the scope of stem cell application in human diseases, disorders, and injuries. For example, in February 2014, Cellular Biomedicine Group, a China-based company, released the six-month follow-up data analysis of its phase 1/2a clinical trial for ReJoin, a human adipose-derived mesenchymal precursor cell (haMPC) therapy for knee osteoarthritis. The study, which tested the safety and efficacy of intra-articular injections of autologous haMPCs to reduce inflammation and repair damaged joint cartilage, showed knee pain was significantly reduced and knee mobility was improved.40 And the journal Stem Cell Research & Therapy reported that researchers at the University of Adelaide in Australia recently completed a project showing stem cells taken from teeth could form complex networks of brain-like cells. Although the cells did not grow into full neurons, the researchers say that it will happen given time and the right conditions.41

In February 2014, the U.S. Court of Appeals for the District of Columbia Circuit upheld a 2012 ruling that a patients stem cells for therapeutic use fall under the aegis of the FDA.42 The appeals case involved the company Regenerative Sciences, which was using patients MSCs in its Regenexx procedure to treat orthopedic problems.43

The FDAs Center for Biologics Evaluation and Research (CBER) regulates human cells, tissues, and cellular and tissue-based products (HCT/P) intended for implantation, transplantation, infusion, or transfer into a human recipient, including hematopoietic stem cells. Under the authority of Section 361 of the Public Health Service Act, the FDA has established regulations for all HCT/Ps to prevent the transmission of communicable diseases.44

The Regenexx case highlights an ongoing debate about whether autologous MSCs are biological drugs subject to FDA approval or simply human cellular and tissue products. Some medical centers collect, concentrate, and reinject MSCs into a patient to treat osteoarthritis but do not add other agents to the injection. The FDA contends that any process that includes culturing, expansion, and added growth factors or antibiotics requires regulation because the process constitutes significant manipulation. Regenerexx has countered that the process does not involve the development of a new drug, which could be given to a number of patients, but rather a patients own MSCs, which affects just that one patient.

Ensuring the safety and efficacy of stem cellbased products is a major challenge, says the FDA. Cells manufactured in large quantities outside their natural environment in the human body can potentially become ineffective or dangerous and produce significant adverse effects such as tumors, severe immune reactions, or growth of unwanted tissue. Even stem cells isolated from a persons own tissue can potentially present these risks when put into an area of the body where they could not perform the same biological function that they were originally performing. Stem cells are immensely complex, the FDA cautionsfar more so than many other FDA-regulated productsand they bring with them unique considerations for meeting regulatory standards.

To date, no U.S. companies have received FDA approval for any autologous MSC therapy, although a study is ongoing to assess the feasibility and safety of autologous MSCs for osteoarthritis.45 One of the major risks with MSCs is that they could potentially lead to cancer or differentiation into bone or cartilage.46

The numerous stem cell studies in progress across the globe are only a first step on the long road toward eventual therapies for degenerative and life-ending diseases. Because of their unlimited ability to self-renew and to differentiate, embryonic stem cells remain, theoretically, a potential source for regenerative medicine and tissue replacement after injury or disease. However, the difficulty of producing large quantities of stem cells and their tendency to form tumors when transplanted are just a few of the formidable hurdles that researchers still face. In the meantime, the shorter-term payoff of using these cells as a tool to better understand diseases has significant implications.

Social and ethical issues around the use of embryonic stem cells must also be addressed. Many nations, including the U.S., have government-imposed restrictions on either embryonic stem cell research or the production of new embryonic stem cell lines. Induced pluripotent stem cells offer new opportunities for development of cell-based therapies while also providing a way around the ethical dilemma of using embryos, but just how good an alternative they are to embryonic cells remains to be seen.

It is clear that many challenges must be overcome before stem cells can be safely, effectively, and routinely used in the clinical setting. However, their potential benefits are numerous and hold tremendous promise for an array of new therapies and treatments.

The authors wish to thank the FDA staff for their support in writing this article and Rachael Conklin, Consumer Safety Officer, Consumer Affairs Branch, Division of Communication and Consumer Affairs, Center for Biologics Evaluation and Research, for her help in organizing the comments provided by FDA staff.

Read more from the original source:
Stem Cell Therapy: a Look at Current Research, Regulations ...

Posted in New Jersey Stem Cells | Comments Off on Stem Cell Therapy: a Look at Current Research, Regulations …

Stem Cells Market to Witness Gigantic Growth by 2026 LSMedia – LSMedia

Posted: December 24, 2021 at 2:11 am

Advance Market Analytics published a new research publication on Stem Cells Market Insights, to 2026 with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Stem Cells Market was mainly driven by the increasing R&D spending across the world.

Some of the key players profiled in the study are:

Smith & Nephew (United Kingdom),Celgene Corporation (United States),BIOTIME, INC. (United States),Cynata (Australia),Applied Cell Technology (Hungary),STEMCELL Technologies Inc. (Canada),BioTime Inc. (United States),Cytori Therapeutics, Inc. (United States),Astellas Pharma Inc. (Japan),U.S. Stem Cell, Inc. (United States),Takara Holdings. (Japan)

Get Free Exclusive PDF Sample Copy of This Research @ https://www.advancemarketanalytics.com/sample-report/72815-global-stem-cells-market-1

Scope of the Report of Stem Cells

The stem cell is used for treating chronic diseases such as cardiovascular disorders, cancer, diabetes, and others. Growing research and development in stem cell isolation techniques propelling market growth. For instance, a surgeon from Turkey developed a method for obtaining stem cells from the human body without enzymes which are generally used for the isolation of stem cells. Further, growing healthcare infrastructure in the developing economies and government spending on the life science research and development expected to drive the demand for stem cell market over the forecasted period.

Market Trend:

Emphasizing On Development of Regenerative Medicine

Technological Advancement in Stem Cell Harvesting and Isolation Techniques

Market Drivers:

Rising Prevalence of Chronic Diseases such as Cardiovascular Disorders, Cancer, and others

Growing Healthcare Infrastructure in the Developing Economies

Challenges:

Lack of Awareness Regarding Stem Cell Therapy in the Low and Middle Income Group Countries

Opportunities:

Growing Demand for Cellular Therapies

Rising Application of Autologous Therapy

The titled segments and sub-section of the market are illuminated below:by Type (Adult Stem Cells (Neuronal, Hematopoietic, Mesenchymal, Umbilical Cord, Others), Human Embryonic Stem Cells (hESC), Induced Pluripotent Stem Cells, Very Small Embryonic-Like Stem Cells), Application (Regenerative Medicine (Neurology, Orthopedics, Oncology, Hematology, Cardiovascular and Myocardial Infraction, Injuries, Diabetes, Liver Disorder, Incontinence, Others), Drug Discovery and Development), Technology (Cell Acquisition (Bone Marrow Harvest, Umbilical Blood Cord, Apheresis), Cell Production (Therapeutic Cloning, In-vitro Fertilization, Cell Culture, Isolation), Cryopreservation, Expansion and Sub-Culture), Therapy (Autologous, Allogeneic)

Have Any Questions Regarding Global Financial Advisory Market Report, Ask Our [emailprotected] https://www.advancemarketanalytics.com/enquiry-before-buy/72815-global-stem-cells-market-1

Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Strategic Points Covered in Table of Content of Global Stem Cells Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Stem Cells market

Chapter 2: Exclusive Summary the basic information of the Stem Cells Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Stem Cells

Chapter 4: Presenting the Stem Cells Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying market size by Type, End User and Region 2015-2020

Chapter 6: Evaluating the leading manufacturers of the Stem Cells market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries (2021-2026).

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Stem Cells Market is a valuable source of guidance for individuals and companies in decision framework.

Read Detailed Index of full Research Study at @ https://www.advancemarketanalytics.com/reports/72815-global-stem-cells-market-1

Contact Us:

Craig Francis (PR & Marketing Manager)AMA Research & Media LLPUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218[emailprotected]

Connect with us athttps://www.linkedin.com/company/advance-market-analyticshttps://www.facebook.com/AMA-Research-Media-LLP-344722399585916https://twitter.com/amareport

Visit link:
Stem Cells Market to Witness Gigantic Growth by 2026 LSMedia - LSMedia

Posted in New Jersey Stem Cells | Comments Off on Stem Cells Market to Witness Gigantic Growth by 2026 LSMedia – LSMedia

Products That Use Aborted Fetuses Nebraska Coalition for …

Posted: December 24, 2021 at 2:10 am

NCER Notes:

Is it ethical to use aborted fetal tissue in research? The practice of using aborted fetal tissue has been in the news lately with the trial of journalist David Daleiden, who filmed Planned Parenthood abortionists admitting they change their procedures in order to sell the freshest aborted fetal tissue to researchers. This kind of research has been ongoing for decades in a shroud of secrecy within a medical community that has become unfazed by the ethical issues involved. Aborted fetal tissue has been used to create everything from vaccines to potential cures for diseases, and is firmly entrenched in research protocol, even when other ethical options are available. Planned Parenthood has become the fetal tissue dealer to both government and private medical research, and as such, reaps financial benefits. Abortion is the flagrant taking of a human life, and the use of aborted tissue, even in pursuit of a cure, completely nullifies the bioethical principles of 1) informed consent, 2) benefit must outweigh the risk and 3) justice toward the most vulnerable. The following article exposes the shockingly common uses of aborted fetal tissue.

ByAndrea Byrnes|April 23rd, 2019

Do some products contain fetal parts? The short gruesome answer: Yes.

Todays consumer products are not the soap and lampshades of recycled Nazi concentration camp victims. The new utilitarian use of people is a sophisticated enterprise, not visible to the human eye.

Perhaps you are a diligent supporter and promoter of pro-life legislation, only vote for pro-life candidates, avoid entertainment from musicians and actors who openly support Planned Parenthood. Regardless, you may unwittingly be cooperating in aborted fetal cell research by purchasing products that use aborted fetuses, either in the product itself or in its development.

One might take Enbrel (Amgen) to relieve Rheumatoid Arthritis. Your husband was given Zoastavax (Merck), a Shingles vaccine, at his annual physical. Your mother with diabetes and renal failure is prescribed Arensep (Amgen). Your grandfather is given the blood product Repro (Eli Lilly) during an angioplasty. The local school district requires that your grandchildren receive the MMRII (the Merck Measles-Mumps-Rubella vaccine). Your daughter and son use coffee creamers and eat soup with artificial flavor enhancers (Senomyx/Firmenich) tested on artificial taste buds engineered from aborted fetal cells.

Because of the vagary of FDA labeling, unless you are proficient at reading patents and pharmaceutical inserts you wouldnt know aborted fetal parts were there without someone to tell you

Luckily, that someone is the watchdog group Children of God for Life (COG), a pro-life public citizen group which tracks the use of aborted fetal parts. Under the leadership of Executive Director Debi Vinnedge, COG publishes adownloadable listof products that use aborted fetuses currently available in the U.S.

Products related to fetal material can be broken down into roughly 3 categories: artificial flavors, cosmetics, and medicines/vaccines.

To be clear, food and beveragesdo notcontain any aborted fetal material; however, they may be tastier because of it. How is that?

The American biotech company Senomyx has developed chemical additives that can enhance flavor and smell. To do this, they had to produce an army of never-tiring taste testersthat is, flavor receptors engineered fromhuman embryonic kidney cells(HEK 293, fetal cell line popular in pharmaceutical research).These artificial taste buds can tell product developers which products the public will crave. The goal is to do a taste bud sleight of hand, creating low-sugar and low-sodium products that taste sweet or salty while actually using less sugar or sodium in the product.

Does your Nestle Coffee-mate Pumpkin Spice refrigerated creamer taste more like autumn? Does your Maggi bouillon taste just like chicken? Thank Senomyx.

The laboratory-created artificial enhancers do not have to be tested at length by the FDA because the Senomyx chemical flavor compounds are used in proportions less than one part per million and can be classified as artificial flavors.

In 2005, Senomyx had contracts to develop products for Kraft Foods, Nestle, Campbell Soup and Coca-Cola.However, when it was discovered in 2011 that PepsiCo was using Senomyx to develop a reduced sugar beverage, a boycott ensued that caused Kraft-Cadbury Adams LLC and Campbell Soup cancelled their contracts with Senomyx. In a 2012 letter to Children of God for Life, PepsiCo stated, Senomyx does not use HEK cells or any other tissues or cell lines derived from human embryos or fetuses for research performed on behalf of PepsiCo.To that effect, PepsiCo is working with Senomyx on two products developed with Sweetmyx 617, a new Senomyx sweet taste modifier.

In November 2018, the Swiss company Firmenich acquired Senomyx, Inc. Firmenich describes itself as a global leader in taste innovation and expert in sweet, cooling and bitter solutions.

The fountain of youthis babies.

Commercially, its known as Processed Skin Proteins (PSP), developed at the University of Lausanne to heal burns and wounds by regenerating traumatized skin. The fetal skin cell line was taken from an electively aborted baby whose body was donated to the University.

Neocutis, a San Francisco-based firm, uses PSP in some of their anti-aging skin products. Their website claims the trademarked PSP harnesses the power of Human Growth Factors, Interleukins and other Cytokines, to help deliver state-of-the-art skin revitalization.

TheVaccine Cardat the Sound Choice Pharmaceutical Institute (SCPI) website lists over 21 vaccines and medical products that contain aborted fetal cell lines. The Card is updated yearly, and also lists ethical vaccine alternatives when there are any.

SCPI is a biomedical research organization headed by Theresa Deisher, who has a PhD in Molecular and Cellular Physiology from Stanford and 23 patents in the field to her name. Dr. Deisher, the first person to identify and patent stem cells from the adult heart, has an insiders understanding of genetic engineering having worked in the industry leaders such as Amgen, Genetech, and Repligen.

Among other things SCPI promotes awareness about the widespread use of fetal human material in drug discovery, development and commercialization.

No vaccine product is completely pure: You will find contaminating DNA and cellular debris from the production cell in your final product. When we switch from using animal cells to using human cells we now have human DNA in our vaccines and our drugs.

The problem is three-fold. Aborted fetal parts are used for experiments, aborted fetal cell lines are used, and fetal cellular DNA debris are in vaccines and medicines.

But it is not just human DNA that is left over, so are some of the chemical stabilizers that keep the product from degrading, as well as, stimulants to rev up the immune system.

Vaccines are a virus that have been put into a vial, in a liquid, which is the buffer, which we call excipients, and companies have put in stabilizers so that the virus wont degrade and other things that kind of rev up your immune system so that they can use lower amounts of the virus and have a greater profit margin. And immune stimulants are things like aluminum andthimerosal, they arestabilizers but they rev up the immunes system, so all of these things are in the final product, including contaminates from the cell lines that are used to manufacture the vaccines.

Why arent the contaminates removed? Because nobody wants a pediatric vaccine that costs a few thousand dollars.

In finance, the yield is inversely related to the price. In chemistry, the yield is inversely related to purity. The price of inexpensive mass-produced vaccines is that the medical establishment accepts that the vaccines contain a high amount of fetal contaminates.

[I]f they have purified out the containments from the cell lines, the yield would be so low that they wouldnt make any money, or no one would pay a thousand dollars or ten thousand dollars for a vaccine. And so because of that case remnants from the cell lines, in that case, fetal cell lines are in the final product. And they are at actually very high levels. And in the chicken pox, the fetal DNAcontaminates are present at twice the levels of the active ingredient which isVaricella DNA.

Much research is currently being done with fetal cells.

We know this because, for one, theres a market for fetal parts. In aseries of undercover videos, David Daleiden ofThe Center for Medical Progressexposed Planned Parenthood abortion clinics selling fetal parts to investigators posing as and medical researchers. And for his efforts his office was raided in 2016 by then California Attorney General Kamala Harris, now a Senator and 2020 Presidential Candidate Harris.Daleiden is currently being pursued in court by current California Attorney General, and former Democrat California Congressman, Xavier Becerra.

We already knew this was happening from the testimony of scientists themselves. On January 11, 2018, professor emeritus Dr. Stanley Plotkin, the lead developer of the Rubella vaccine for the Wistar Institute (Philadelphia) in the 1960s, was deposed as an expert witness on Vaccinology in a Michigan child custody case.Dr. Plotkin was asked how many aborted fetuses he has used in his experiments:

QUESTION: So in your, in all of your work related to vaccines throughout your whole career, youve only ever worked with two fetuses?

PLOTKIN: In terms of making vaccines, yes.

But after being presented with Exhibit 41 (Proceedings of the Society of Experimental Biology and Medicine), the two fetuses involved in his experiment grows exponentially to 76 aborted fetuses.

QUESTION: So this study involved 74 fetuses, correct?

PLOTKIN: Seventy-six.

QUESTION: And these fetuses were all three months or older when aborted, correct? PLOTKIN: Yes.

A true enough response. Fetal cells, for that matter all normal cells, have a finite capacity to replicate following the principle of cellular aging. The vaccine trail needed many cell lines in order to achieve its end.

An interesting aside: during questioning Dr. Plotkin answered affirmatively that some of his subjects for experimental vaccine trials had been children of mothers in prison, the mentally ill, and individuals under colonial rule [Belgian Congo].

Dr. Theresa Deisher first became aware of the introduction of fresh aborted fetal material in drug discovery in 1996.Fresh fetal parts are a time-saver compared to the days spent washing and prepping animal tissue, like monkey hearts, for laboratory experiments. While it is not legal to sell aborted fetal tissue, it is still available in catalogues and comes with high prices for shipping and handling.

According to Dr. David A. Prentice Vice, President of the Charlotte Lozier Institute and Adjunct Professor of Molecular Genetics at the John Paul II Institute,adult stem cellsare the benchmark for research that has led to actual cures for patients.

The superiority of adult stem cells in the clinic and the mounting evidence supporting their effectiveness in regeneration and repair make adult stem cells the gold standard of stem cells for patients.

Then why are we still using embryonic cell lines when adult stem cells have become the Gold Standard? There seems to be little excuse for products that use aborted fetuses.

embryonic stem cells

On the 20th Anniversary of Roe v. Wade in 1993, President Clinton signed five abortion-related memorandums which included the reversal of the George H. W. Bush era moratorium on creating new fetal tissue for research, claiming at the time, This moratorium has significantly hampered the development of possible treatments for individuals afflicted with serious diseases and disorders, such as Parkinsons disease, Alzheimers disease, diabetes and leukemia.

While a bio-ethics debate transfixed the country in 2006 as to whether the United States would allow the use of new aborted fetal stem cells in research, [see White HouseFact Sheet on Stem Cell Research Policy], the medical research community had already decided that the future lay with human-animal hybrids and new aborted fetal cell lines. According to a statement submitted to the Presidents Bioethics Council:

Aborted human DNA in our vaccines is not the end, it is only the beginning, as the creation of human-animal hybrids demonstrates. A new aborted fetal cell line has been developed, called PerC6, and licenses have been taken by over 50 partners, including the NIH and the Walter Reed Army Institute, to use this cell line for new vaccine and biologics production. The goal of the company that created the PerC6 is to become the production cell line for ALL vaccines, therapeutics antibodies, biologic drugs and gene therapy.

And this has largely come to pass.

In 2019, the Department of Health and Human Services granted a second 90-day extension to a contract it has with the University of California at San Francisco that requires UCSF to make humanized mice for on-going AIDS research. The human fetal tissue comes from late-term abortions.

CNSNews reported that according to an estimate it haspublished on its website, the National Institutes of Health (which is a division of HHS) will spend $95 million this fiscal year alone on research thatlike UCSFs humanized mouse contractuses human fetal tissue.

Seeherefor news on how the Trump administration limited the sale of fetal parts.

Stop Ebola? Prevent Zika Virus? Cure AIDS? Look for more, not fewer, aborted fetal products in the future.

Full Article with links and footnotes here

Writer Andrea Byrnes was the first producer of U.S. March for Life coverage at EWTN Global Catholic Network, which she continued to supervise for seven years. She attended her first HLI conference in 1989, where she first met Servant of God Dr. Jerome Lejeune. She and her husband would later pray for Lejeunes intercession for her sons health difficulties discovered before birth, and thanks be to God, he is thriving.

More here:
Products That Use Aborted Fetuses Nebraska Coalition for ...

Posted in Nebraska Stem Cells | Comments Off on Products That Use Aborted Fetuses Nebraska Coalition for …

People in the News: New Appointments at NIH, Predicine, Mainz Biomed, Bio-Techne, More – GenomeWeb

Posted: December 24, 2021 at 2:08 am

National Institutes of Health: Holly Garriock

Holly Garriock has been appointed as chief cohort development officer of the National Institutes of Health's All of Us research program. Since 2016, she has held several roles at All of Us, including deputy director for the division of scientific programs and program officer for the effort's healthcare provider organizations. Before that, she was a program officer at the National Institute of Mental Health. Garriock holds an undergraduate degree from Bishop's University in Canada and a PhD in genetics from the University of Arizona.

Predicine: Linh Le

Linh Le has been appointed as CFO of Predicine. He comes to the molecular diagnostics company from Ambry Genetics, where he was chief operating officer. Previously, he spent more than 14 years overseeing financial operations and global expansion at Medtronic's Diabetes Group.

Mainz Biomed: Karen Richards

Mainz Biomed has appointed Karen Richards as VP of regulatory affairs. She will also serve as SVP of in vitro diagnostics and quality at Precision for Medicine. According to Mainz Biomed, Richards was responsible for the approval of laboratory tests in all 50 states in the US requiring a license and has implemented quality systems for diagnostic products to meet various regulatory and certification requirements, including those of the US Food and Drug Administration, CLIA, and the College of American Pathologists.

Bio-Techne: William Geist, David Eansor

Bio-Techne has appointed William Geist as president of its protein sciences segment, effective Jan. 3, 2022. Geist was most recently chief operating officer at Quanterix, where he was responsible for enterprise-wide operations and strategy deployment. Previously, he was VP and general manager for Thermo Fisher Scientific's protein and cell analysis and qPCR business units, and VP of Qiagen's QuantaBiosciences.

Geist succeeds David Eansor, who is retiring and will remain with Bio-Techne through the end of February 2022 to ensure a smooth transition.

For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.

See the article here:
People in the News: New Appointments at NIH, Predicine, Mainz Biomed, Bio-Techne, More - GenomeWeb

Posted in Molecular Genetics | Comments Off on People in the News: New Appointments at NIH, Predicine, Mainz Biomed, Bio-Techne, More – GenomeWeb

Open letter to employees, technologists, professionals and physicians of the Optilab laboratory medicine clusters in Quebec – McGill University Health…

Posted: December 24, 2021 at 2:08 am

We, the medical and clinical-administrative directors of the Optilab laboratory medicine clusters in Quebec, sincerely thank you for your hard work and dedication. In the extremely challenging context of COVID-19 for laboratory personnel, you put all your expertise and energy into serving Quebecers every day to provide reliable laboratory analyses that are essential to care.

Thanks to you, millions of molecular virology COVID screening tests have been performed in microbiology departments. Your work has enabled the development of sophisticated new assays using next generation gene sequencing in the molecular genetics departments. These analyses are now available to the Quebec population for personalized cancer medicine. Thanks to you, thousands of detailed examination of tissue and their characteristics, on which most treatment decisions depend, are made every day in the pathology services. In addition, sophisticated coagulation analyses are made in hematology services for the management of people with hemophilia and high-throughput tests of pharmacological molecules are completed in biochemistry services. Furthermore, through the analyses performed in the transfusion medicine departments, you allow decisions to be made that are sometimes vital in emergency situations.

These examples represent a small fraction of the procedures performed every day in the clinical laboratories of Quebec hospitals. None of this would be possible without you. You are this network and we are immensely proud and honored to work alongside you.

We thank you for all the work you do in the laboratories of Quebec hospitals, for your willingness and your talent. We wish you and your loved ones happy holidays and a Happy New Year!

Dany Aubry, Ren Bergeron, Mlanie Bernard, Normand Brassard, Enzo Caprio, Dr. Christian Carrier, Martin Coulombe, Dr. Jean-Franois Dermine, Dr. Jean Dub, Dr. Linda Lalancette, Bruno Lamontagne, Dr. Emmanuelle Lemyre, Dr. Franois Lessard, Andr Lortie, Dr. Daniele Marceau, Zied Ouechteti, Dr. Jean-Franois Paradis, Genevive Plante, Annie Robitaille, Dr. Benot Samson, Dr. Alan Spatz, Sylvie Thibeault, Sophie Verdon, Dr. Andr Vincent, Dr. Ewa Barbara Wesolowska

See the original post here:
Open letter to employees, technologists, professionals and physicians of the Optilab laboratory medicine clusters in Quebec - McGill University Health...

Posted in Molecular Genetics | Comments Off on Open letter to employees, technologists, professionals and physicians of the Optilab laboratory medicine clusters in Quebec – McGill University Health…

Recently Evolved Region of the Dark Genome Offers Clues to Treatment of Schizophrenia and Bipolar Disorder – SciTechDaily

Posted: December 24, 2021 at 2:08 am

Scientists investigating the DNA outside our genes the dark genome have discovered recently evolved regions that code for proteins associated with schizophrenia and bipolar disorder.

They say these new proteins can be used as biological indicators to distinguish between the two conditions, and to identify patients more prone to psychosis or suicide.

Schizophrenia and bipolar disorder are debilitating mental disorders that are hard to diagnose and treat. Despite being amongst the most heritable mental health disorders, very few clues to their cause have been found in the sections of our DNA known as genes.

The scientists think that hotspots in the dark genome associated with the disorders may have evolved because they have beneficial functions in human development, but their disruption by environmental factors leads to susceptibility to, or development of, schizophrenia or bipolar disorder.

The results are published today (December 23, 2021) in the journal Molecular Psychiatry.

By scanning through the entire genome weve found regions, not classed as genes in the traditional sense, which create proteins that appear to be associated with schizophrenia and bipolar disorder, said Dr Sudhakaran Prabakaran, who was based in the University of Cambridges Department of Genetics when he conducted the research, and is senior author of the report.

He added: This opens up huge potential for new druggable targets. Its really exciting because nobody has ever looked beyond the genes for clues to understanding and treating these conditions before.

The researchers think that these genomic components of schizophrenia and bipolar disorder are specific to humans the newly discovered regions are not found in the genomes of other vertebrates. It is likely that the regions evolved quickly in humans as our cognitive abilities developed, but they are easily disrupted resulting in the two conditions.

The traditional definition of a gene is too conservative, and it has diverted scientists away from exploring the function of the rest of the genome, said Chaitanya Erady, a researcher in the University of Cambridges Department of Genetics and first author of the study.

She added: When we look outside the regions of DNA classed as genes, we see that the entire human genome has the ability to make proteins, not just the genes. Weve found new proteins that are involved in biological processes and are dysfunctional in disorders like schizophrenia and bipolar disorder.

The majority of currently available drugs are designed to target proteins coded by genes. The new finding helps to explain why schizophrenia and bipolar disorder are heritable conditions, and could provide new targets for future treatments.

Schizophrenia is a severe, long-term mental health condition that may result in hallucinations, delusions, and disordered thinking and behavior, while bipolar disorder causes extreme mood swings ranging from mania to depression. The symptoms sometimes make the two disorders difficult to tell apart.

Prabakaran left his University position earlier this year to create the company NonExomics, in order to commercialize this and other discoveries. Cambridge Enterprise, the commercialization arm of the University of Cambridge, has assisted NonExomics by licensing the intellectual property. Prabakaran has raised seed funding to develop new therapeutics that will target the proteins implicated in schizophrenia and bipolar disorder, and other diseases.

His team has now discovered 248,000 regions of DNA outside of the regions conventionally defined as genes, which code for new proteins that are disrupted in disease.

Reference: Novel open reading frames in human accelerated regions and transposable elements reveal new leads to understand schizophrenia and bipolar disorder by Chaitanya Erady, Krishna Amin, Temiloluwa O. A. E. Onilogbo, Jakub Tomasik, Rebekah Jukes-Jones, Yagnesh Umrania, Sabine Bahn and Sudhakaran Prabakaran, 23 December 2021, Molecular Psychiatry.DOI: 10.1038/s41380-021-01405-6

View original post here:
Recently Evolved Region of the Dark Genome Offers Clues to Treatment of Schizophrenia and Bipolar Disorder - SciTechDaily

Posted in Molecular Genetics | Comments Off on Recently Evolved Region of the Dark Genome Offers Clues to Treatment of Schizophrenia and Bipolar Disorder – SciTechDaily

Page 575«..1020..574575576577..580590..»